Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 3;9(1):15.
doi: 10.3390/jfmk9010015.

Exercise-Induced Asthma: Managing Respiratory Issues in Athletes

Affiliations
Review

Exercise-Induced Asthma: Managing Respiratory Issues in Athletes

Josuel Ora et al. J Funct Morphol Kinesiol. .

Abstract

Asthma is a complex respiratory condition characterized by chronic airway inflammation and variable expiratory airflow limitation, affecting millions globally. Among athletes, particularly those competing at elite levels, the prevalence of respiratory conditions is notably heightened, varying between 20% and 70% across specific sports. Exercise-induced bronchoconstriction (EIB) is a common issue among athletes, impacting their performance and well-being. The prevalence rates vary based on the sport, training environment, and genetics. Exercise is a known trigger for asthma, but paradoxically, it can also improve pulmonary function and alleviate EIB severity. However, athletes' asthma phenotypes differ, leading to varied responses to medications and challenges in management. The unique aspects in athletes include heightened airway sensitivity, allergen, pollutant exposure, and temperature variations. This review addresses EIB in athletes, focusing on pathogenesis, diagnosis, and treatment. The pathogenesis of EIB involves complex interactions between physiological and environmental factors. Airway dehydration and cooling are key mechanisms, leading to osmotic and thermal theories. Airway inflammation and hyper-responsiveness are common factors. Elite athletes often exhibit distinct inflammatory responses and heightened airway sensitivity, influenced by sport type, training, and environment. Swimming and certain sports pose higher EIB risks, with chlorine exposure in pools being a notable factor. Immune responses, lung function changes, and individual variations contribute to EIB in athletes. Diagnosing EIB in athletes requires objective testing, as baseline lung function tests can yield normal results. Both EIB with asthma (EIBA) and without asthma (EIBwA) must be considered. Exercise and indirect bronchoprovocation tests provide reliable diagnoses. In athletes, exercise tests offer effectiveness in diagnosing EIB. Spirometry and bronchodilation tests are standard approaches, but the diagnostic emphasis is shifting toward provocation tests. Despite its challenges, achieving an optimal diagnosis of EIA constitutes the cornerstone for effective management, leading to improved performance, reduced risk of complications, and enhanced quality of life. The management of EIB in athletes aligns with the general principles for symptom control, prevention, and reducing complications. Non-pharmacological approaches, including trigger avoidance and warming up, are essential. Inhaled corticosteroids (ICS) are the cornerstone of asthma therapy in athletes. Short-acting beta agonists (SABA) are discouraged as sole treatments. Leukotriene receptor antagonists (LTRA) and mast cell stabilizing agents (MCSA) are potential options. Optimal management improves the athletes' quality of life and allows them to pursue competitive sports effectively.

Keywords: asthma; athletes; exercise-induced bronchospasm.

PubMed Disclaimer

Conflict of interest statement

J.O. participated as a speaker in scientific meetings and courses under the sponsorship of AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Novartis, and Zambon. P.D.M. has no conflicts of interest to declare. M.G. has no conflicts of interest to declare. M.C. participated as a lecturer and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, Edmond Pharma, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis, and her department was funded by Almirall, Boehringer Ingelheim, Chiesi Farmaceutici, Novartis, and Zambon. P.R. participated as a lecturer and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, Edmond Pharma, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis, and her department was funded by Almirall, Boehringer Ingelheim, Chiesi Farmaceutici, Novartis, and Zambon.

Figures

Figure 1
Figure 1
Flow chart outlining the process of combining multiple tests in the diagnosis of EIB.

Similar articles

Cited by

References

    1. Global Initiative for Asthma GINA 2023. [(accessed on 2 November 2023)]. Available online: https://ginasthma.org/2023-gina-main-report/
    1. GBD 2019 Diseases and Injuries Collaborators Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–1222. doi: 10.1016/S0140-6736(20)30925-9. - DOI - PMC - PubMed
    1. Price O.J., Sewry N., Schwellnus M., Backer V., Reier-Nilsen T., Bougault V., Pedersen L., Chenuel B., Larsson K., Hull J.H. Prevalence of lower airway dysfunction in athletes: A systematic review and meta-analysis by a subgroup of the IOC consensus group on ‘acute respiratory illness in the athlete’. Br. J. Sports Med. 2021;56:213–222. doi: 10.1136/bjsports-2021-104601. - DOI - PubMed
    1. Melsom H.S., Randa A., Hisdal J., Stang J.S., Stensrud T. Prevalence of Asthma among Norwegian Elite Athletes. Calbet JAL, editor. [(accessed on 5 October 2023)];Transl. Sports Med. 2022 2022:1–10. doi: 10.1155/2022/3887471. Available online: https://www.hindawi.com/journals/tsmed/2022/3887471/ - DOI - PMC - PubMed
    1. Lund T., Pedersen L., Larsson B., Backer V. Prevalence of asthma-like symptoms, asthma and its treatment in elite athletes. Scand. J. Med. Sci. Sports. 2008;19:174–178. doi: 10.1111/j.1600-0838.2007.00753.x. - DOI - PubMed

LinkOut - more resources